GUD Knight Therapeutics

Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

MONTREAL, April 15, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 21, 2026, at 2:00 p.m. ET at the Metro Toronto Convention Centre (North Building) in Toronto. A copy of the presentation will be available at .

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or .

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2025, as filed on . Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

CONTACT INFORMATION:

Investor Contact:  
Knight Therapeutics Inc.  


Samira Sakhia
 

Arvind Utchanah
President & Chief Executive Officer Chief Financial Officer
T: 514.484.4483 T. +598.2626.2344
F: 514.481.4116  
Email:  Email: 
Website:  Website: 


EN
15/04/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Knight Therapeutics

 PRESS RELEASE

Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor C...

Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference MONTREAL, April 15, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 21, 2026, at 2:00 p.m. ET at the Metro Toronto Convention Centre (North Building) in Toronto. A copy of the presentation will be available at . About Knight Therapeut...

 PRESS RELEASE

Knight présentera à la conférence des investisseurs en santé Bloom Bur...

Knight présentera à la conférence des investisseurs en santé Bloom Burton & Co. 2026 MONTRÉAL, 15 avr. 2026 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD), société pharmaceutique spécialisée panaméricaine (ex-ÉU), a annoncé aujourd'hui que Samira Sakhia, présidente et chef de la direction, présentera une mise à jour corporative à la conférence des investisseurs en santé Bloom Burton & Co. 2026, le mardi 21 avril 2026 à 14 h 00 HE au Metro Toronto Convention Centre (bâtiment Nord) à Toronto. Une copie de la présentation sera disponible sur . À propos de Thérapeutique Knight inc...

 PRESS RELEASE

Knight Therapeutics Inc. ranks on The Globe and Mail’s second annual C...

Knight Therapeutics Inc. ranks on The Globe and Mail’s second annual Canada’s Top Growing Women-Led Companies and seventh annual Women Lead Here benchmark of executive gender diversity MONTREAL, March 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it has been recognized on two of The Globe and Mail’s Report on Business magazine’s 2026 national benchmarks: Canada’s Top Growing Women-Led Companies, now in its second year, which highlights Canadian women-led businesses; andWomen Lead Here, now in its seventh year, which id...

 PRESS RELEASE

Thérapeutique Knight inc. se mérite une place à la deuxième édition du...

Thérapeutique Knight inc. se mérite une place à la deuxième édition du classement du Globe and Mail Canada’s Top Growing Women-Led Companies et à la septième édition de celui de Women Lead Here sur la diversité des femmes dirigeantes MONTRÉAL, 27 mars 2026 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou « la Société ») a le plaisir d’annoncer sa nomination à deux classements nationaux du magazine 2026 du Globe and Mail’s Report on Business : Le classement Canada’s Top Growing Women-Led Companies, à sa deuxième édition, qui met en valeur les sociétés canadiennes g...

 PRESS RELEASE

Knight Amends Normal Course Issuer Bid

Knight Amends Normal Course Issuer Bid MONTREAL, March 23, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"), a pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") to amend the Company’s previously announced Notice of Intention to Make a Normal Course Issuer Bid ("NCIB") to increase the maximum number of common shares (the “Common Shares”) that it intends to repurchase for cancellation during the 12-month period ending August 21, 2026, from 3,000,000 Common Shares to 6,190,493 Com...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch